Oct. 17, 2024 — In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in ... New Study Finds a ...

Many people living with the degenerative neurological disease multiple sclerosis (MS) are premenopausal women. This means ...

Early signs of multiple sclerosis can include blurry vision ... specific biomarkers that can help to understand who is more likely to develop MS after a CIS episode. Not everyone does, and there are ...

Oct. 17, 2024 — In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in ... New Study Finds a ...

ACT-10041239 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Multiple Sclerosis.

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...

OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...

ANK-700 is under clinical development by Anokion and currently in Phase I for Relapsing Remitting Multiple Sclerosis (RRMS).

Long-term Tecfidera use was found to significantly reduce relapse rates and slow disability progression for MS patients in a ...

BC, MSCN has joined the Memory Clinic staff. Penny is board-certified in Family Practice with focused training in certain ...

The world’s largest study of proteins circulating the human body will begin in the UK this month, with the aim of pinpointing ...

Although multiple sclerosis (MS) does not typically reduce life expectancy, there has been relatively little systematic investigation of the experiences and health-related concerns of people aging ...